Professor Marios Politis
Director of Mireille Gillings Neuroimaging Centre
m.politis@exeter.ac.uk
Overview
Professor Marios Politis (MD MSc DIC PhD FRCP FEAN) is a Professor of Neurology, Consultant Neurologist, the Director of Neurodegeneration Imaging Group and the Director of Mireille Gillings Neuroimaging Centre at the University of Exeter.
Professor Marios Politis has received a high number of awards for clinical, research, and clinical research excellence including a research achievement award by the MRC (2010), the Movement Disorder Society Award for Outstanding and Innovative Clinical Research (2012), the IMPETus award for innovative and outstanding PET molecular imaging research (2013, 2014, 2015, 2016) and the PET Investigator Award from the Society of Nuclear Medicine and Molecular Imaging (2015). In 2016, he was elected Fellow of the European Academy of Neurology for outstanding contribution in neurodegenerative research. In 2017, he received the Jon Stolk Award in Movement Disorders from the American Academy of Neurology and was elected Fellow of Royal College of Physicians.
Professor Marios Politis has significant industry experience by serving as a clinical investigator, consultant and principal investigator in several collaborations with industrial partners and pharma including a number of clinical trials. He has trained over 120 clinical and non-clinical fellows, research associates and research assistants, and undergraduate and postgraduate students at NIG. He has raised a record amount of over £60 million for cutting-edge research in neurodegenerative conditions such as Parkinson’s disease, Alzheimer’s disease and other neurodegenerative disorders; he is actively collaborating with a high number of philanthropic, government, non-commercial and commercial industrial partners. Professor Marios Politis has published over 150 high impact papers and has been running a specialist Neurology and Movement Disorder clinical service for over 15 years with previous appointments at UCLH, Hammersmith and Charing Cross Hospitals, and King’s College Hospital. He has clinical Consultant contracts with the Royal Devon and Exeter NHS Foundation Trust and the Imperial College Healthcare NHS Trust.
Qualifications
- 2004 – University of Athens, MD
- 2007 – Imperial College London, MSc
- 2010 – Imperial College London, PhD
- 2016 – Fellow of European Academy of Neurology
- 2017 – Fellow of Royal College of Physicians
Research
Research interests
Professor Marios Politis research involves the use of Positron Emission Tomography (PET) and Single Photon Emission Tomography (SPECT) molecular imaging, structural and functional Magnetic Resonance Imaging (MRI), CSF and blood molecular markers, digital markers and clinical observation as methods of investigating aetiology, pathophysiology, and effects and complications of novel therapies in Neurodegenerative disorders.
Publications
Books
Politis M (2019). Preface.
Journal articles
Astara K, Pournara C, de Natale ER, Wilson H, Vavougios GD, Lappas AS, Politis M, Christodoulou NG (2023). A novel conceptual framework for the functionality of the glymphatic system. J Neurophysiol, 129(5), 1228-1236. Abstract. Author URL.
Qamar MA, Sauerbier A, Politis M, Carr H, Loehrer PA, Chaudhuri KR (2023). Author Correction: Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis? (npj Parkinson's Disease, (2017), 3, 1, (5), 10.1038/s41531-016-0006-9). npj Parkinson's Disease, 9(1). Abstract.
Erritzoe D, Godlewska BR, Rizzo G, Searle GE, Agnorelli C, Lewis Y, Ashok AH, Colasanti A, Boura I, Farrell C, et al (2023). Brain Serotonin Release is Reduced in Patients with Depression: a [<sup>11</sup>C]Cimbi-36 Positron Emission Tomography Study with a d-Amphetamine Challenge. Biological Psychiatry, 93(12), 1089-1098. Abstract.
Ford J, Kafetsouli D, Wilson H, Udeh-Momoh C, Politis M, AhmadiAbhari S, Rabiner I, Middleton LT (2022). At a Glance: an Update on Neuroimaging and Retinal Imaging in Alzheimer's Disease and Related Research. J Prev Alzheimers Dis, 9(1), 67-76. Abstract. Author URL.
Wilson H, Pagano G, Yousaf T, Polychronis S, De Micco R, Giordano B, Niccolini F, Politis M (2022). Correction to: Predict cognitive decline with clinical markers in Parkinson's disease (PRECODE-1). J Neural Transm (Vienna), 129(10). Author URL.
Siderowf A, Seibyl J, Coffey C, Tosun-Turgut D, Shaw LM, Trojanowski JQ, Singleton A, Kieburtz K, Toga A, Mollenhauer B, et al (2022). Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort. npj Parkinson's Disease, 8(1).
de Natale ER, Wilson H, Politis M (2022). Predictors of RBD progression and conversion to synucleinopathies. Curr Neurol Neurosci Rep, 22(2), 93-104. Abstract. Author URL.
Wilson H, de Natale ER, Politis M (2022). Recent Advances in Neuroimaging Techniques to Assist Clinical Trials on Cell-Based Therapies in Neurodegenerative Diseases. Stem Cells, 40(8), 724-735. Abstract. Author URL.
Verghese JP, Terry A, de Natale ER, Politis M (2022). Research Evidence of the Role of the Glymphatic System and its Potential Pharmacological Modulation in Neurodegenerative Diseases. J Clin Med, 11(23). Abstract. Author URL.
Chandra A, Farrell C, Wilson H, Dervenoulas G, De Natale ER, Politis M (2021). Aquaporin-4 polymorphisms predict amyloid burden and clinical outcome in the Alzheimer's disease spectrum. Neurobiology of Aging, 97, 1-9.
King-Robson J, Wilson H, Politis M, Alzheimer’s Disease Neuroimaging Initiative (2021). Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment. J Alzheimers Dis, 82(2), 541-560. Abstract. Author URL.
Politis M (2021). Erratum to “The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease” [Park. Relat. Disord. 77C (2021) 163–169/3948] (Parkinsonism and Related Disorders (2020) 77 (163–169), (S1353802019300732), (10.1016/j.parkreldis.2019.02.027)). Parkinsonism and Related Disorders, 88, 58-59. Abstract.
Simuni T, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, et al (2020). Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. The Lancet Neurology, 19(1), 71-80. Abstract.
Carotenuto A, Wilson H, Giordano B, Caminiti SP, Chappell Z, Williams SCR, Hammers A, Silber E, Brex P, Politis M, et al (2020). Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications. Journal of Neurology, 267(7), 2042-2053. Abstract.
Wilson H, Pagano G, de Natale ER, Mansur A, Caminiti SP, Polychronis S, Middleton LT, Price G, Schmidt KF, Gunn RN, et al (2020). Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug-Naive Parkinson's Disease. Mov Disord, 35(8), 1416-1427. Abstract. Author URL.
Wilson H, Politis M, Rabiner EA, Middleton LT (2020). Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases. Cells, 9(12), 2581-2581. Abstract.
Wilson H, Pagano G, Niccolini F, Muhlert N, Mehta MA, Searle G, Gunn RN, Rabiner EA, Foltynie T, Politis M, et al (2020). The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. Parkinsonism and Related Disorders, 77, 163-169. Abstract.
Carotenuto A, Giordano B, Dervenoulas G, Wilson H, Veronese M, Chappell Z, Polychronis S, Pagano G, Mackewn J, Turkheimer FE, et al (2020). [18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis. Eur J Nucl Med Mol Imaging, 47(2), 366-378. Abstract. Author URL.
Chandra A, Valkimadi P-E, Pagano G, Cousins O, Dervenoulas G, Politis M, Alzheimer's Disease Neuroimaging Initiative (2019). Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. Hum Brain Mapp, 40(18), 5424-5442. Abstract. Author URL.
Norgaard M, Ganz M, Svarer C, Feng L, Ichise M, Lanzenberger R, Lubberink M, Parsey RV, Politis M, Rabiner EA, et al (2019). Cerebral serotonin transporter measurements with [<SUP>11</SUP>C]DASB: a review on acquisition and preprocessing across 21 PET centres. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 39(2), 210-222. Author URL.
Pagano G, Niccolini F, Wilson H, Yousaf T, Khan NL, Martino D, Plisson C, Gunn RN, Rabiner EA, Piccini P, et al (2019). Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. Movement Disorders, 34(10), 1505-1515. Abstract.
Wilson H, Niccolini F, Pellicano C, Politis M (2019). Cortical thinning across Parkinson's disease stages and clinical correlates. JOURNAL OF THE NEUROLOGICAL SCIENCES, 398, 31-38. Author URL.
Wilson H, Pagano G, Politis M (2019). Dementia spectrum disorders: lessons learnt from decades with PET research. JOURNAL OF NEURAL TRANSMISSION, 126(3), 233-251. Author URL.
Polychronis S, Dervenoulas G, Yousaf T, Niccolini F, Pagano G, Politis M (2019). Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naive Parkinson's patients. PLOS ONE, 14(7). Author URL.
Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, et al (2019). Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). PARKINSONISM & RELATED DISORDERS, 62, 201-209. Author URL.
Wilson H, Dervenoulas G, Pagano G, Tyacke RJ, Polychronis S, Myers J, Gunn RN, Rabiner EA, Nutt D, Politis M, et al (2019). Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo11C-BU99008 PET study. Brain, 142(10), 3116-3128. Abstract. Author URL.
Chandra A, Dervenoulas G, Politis M (2019). Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment. JOURNAL OF NEUROLOGY, 266(6), 1293-1302. Author URL.
Yousaf T, Dervenoulas G, Valkimadi P-E, Politis M (2019). Neuroimaging in Lewy body dementia. JOURNAL OF NEUROLOGY, 266(1), 1-26. Author URL.
Yousaf T, Pagano G, Niccolini F, Politis M (2019). Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2). JOURNAL OF NEUROLOGY, 266(5), 1203-1210. Author URL.
Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, et al (2019). Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study (Publication with Expression of Concern). LANCET NEUROLOGY, 18(8), 748-759. Author URL.
Niccolini F, Wilson H, Giordano B, Diamantopoulos K, Pagano G, Chaudhuri KR, Politis M (2019). Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson's disease. BMC Neuroscience, 20(1). Abstract.
Polychronis S, Niccolini F, Pagano G, Yousaf T, Politis M (2019). Speech difficulties in early de novo patients with Parkinson's disease. Parkinsonism and Related Disorders, 64, 256-261. Abstract.
Li W, Lao-Kaim NP, Roussakis AA, Martin-Bastida A, Valle-Guzman N, Paul G, Loane C, Widner H, Politis M, Foltynie T, et al (2018). <SUP>11</SUP>C-PE2I and <SUP>18</SUP>F-Dopa PET for Assessing Progression Rate in Parkinson's: a Longitudinal Study. MOVEMENT DISORDERS, 33(1), 117-127. Author URL.
Pagano G, Yousaf T, Wilson H, Niccolini F, Polychronis S, Chaudhuri KR, Politis M (2018). Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease. European Journal of Neurology, 25(2), 307-312. Abstract.
Pagano G, Polychronis S, Wilson H, Giordano B, Ferrara N, Niccolini F, Politis M (2018). Diabetes mellitus and Parkinson disease. NEUROLOGY, 90(19), E1654-E1662. Author URL.
Niccolini F, Wilson H, Hirschbichler S, Yousaf T, Pagano G, Whittington A, Caminiti SP, Erro R, Holton JL, Jaunmuktane Z, et al (2018). Disease-related patterns of in vivo pathology in Corticobasal syndrome. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 45(13), 2413-2425. Author URL.
Noyce AJ, Dickson J, Rees RN, Bestwick JP, Isaias IU, Politis M, Giovannoni G, Warner TT, Lees AJ, Schrag A, et al (2018). Dopamine Reuptake Transporter-Single-Photon Emission Computed Tomography and Transcranial Sonography as Imaging Markers of Prediagnostic Parkinson's Disease. MOVEMENT DISORDERS, 33(3), 478-482. Author URL.
Yousaf T, Pagano G, Niccolini F, Politis M (2018). Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. JOURNAL OF THE NEUROLOGICAL SCIENCES, 387, 220-227. Author URL.
Strafella AP, Bohnen NI, Pavese N, Vaillancourt DE, van Eimeren T, Politis M, Tessitore A, Ghadery C, Lewis S (2018). Imaging Markers of Progression in Parkinson's Disease. Movement Disorders Clinical Practice, 5(6), 586-596. Abstract.
Yousaf T, Pagano G, Niccolini F, Politis M (2018). Increased dopaminergic function in the thalamus is associated with excessive daytime sleepiness. SLEEP MEDICINE, 43, 25-30. Author URL.
Yousaf T, Pagano G, Wilson H, Politis M (2018). Neuroimaging of Sleep Disturbances in Movement Disorders. FRONTIERS IN NEUROLOGY, 9 Author URL.
Schulz J, Pagano G, Bonfante JAF, Wilson H, Politis M (2018). Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease. BRAIN, 141, 1501-1516. Author URL.
Niccolini F, Mencacci NE, Yousaf T, Rabiner EA, Salpietro V, Pagano G, Balint B, Efthymiou S, Houlden H, Gunn RN, et al (2018). PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology. MOVEMENT DISORDERS, 33(12), 1961-1965. Author URL.
Hervé Du Penhoat MA, Moraga NR, Gaigeot MP, Vuilleumier R, Tavernelli I, Politis MF (2018). Proton Collision on Deoxyribose Originating from Doubly Ionized Water Molecule Dissociation. Journal of Physical Chemistry A, 122(24), 5311-5320. Abstract.
Pagano G, De Micco R, Yousaf T, Wilson H, Chandra A, Politis M (2018). REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. NEUROLOGY, 91(10), E894-E905. Author URL.
Wilson H, Giordano B, Turkheimer FE, Chaudhuri KR, Politis M (2018). Serotonergic dysregulation is linked to sleep problems in Parkinson's disease. NEUROIMAGE-CLINICAL, 18, 630-637. Author URL.
Niccolini F, Pagano G, Fusar-Poli P, Wood A, Mrzljak L, Sampaio C, Politis M (2018). Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 89(2), 185-196. Author URL.
Pagano G, Niccolini F, Politis M (2018). The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies. JOURNAL OF NEURAL TRANSMISSION, 125(8), 1217-1223. Author URL.
Politis M (2017). A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism (Niccolini and Politis, 2016). EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 44(3), 548-550. Author URL.
Politis M, Wilson H, Wu K, Brooks DJ, Piccini P (2017). Chronic exposure to dopamine agonists affects the integrity of striatal D<sub>2</sub> receptors in Parkinson's patients. NEUROIMAGE-CLINICAL, 16, 455-460. Author URL.
Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C (2017). Cognitive decline in Parkinson disease. Nat Rev Neurol, 13(4), 217-231. Abstract. Author URL.
Politis M (2017). Disease progression in <i>LRRK2</i> parkinsonism. LANCET NEUROLOGY, 16(5), 334-335. Author URL.
Moonga I, Niccolini F, Wilson H, Pagano G, Politis M (2017). Hypertension is associated with worse cognitive function and hippocampal hypometabolism in Alzheimer's disease. European Journal of Neurology, 24(9), 1173-1182. Abstract.
Politis M, Lahiri N, Niccolini F, Su P, Wu K, Giannetti P, Scahill RI, Turkheimer FE, Tabrizi SJ, Piccini P, et al (2017). Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers (vol 83, pg 115, 2015). NEUROBIOLOGY OF DISEASE, 98, 162-162. Author URL.
Niccolini F, Wilson H, Pagano G, Coello C, Mehta MA, Searle GE, Gunn RN, Rabiner EA, Foltynie T, Politis M, et al (2017). Loss of phosphodiesterase 4 in Parkinson disease Relevance to cognitive deficits. NEUROLOGY, 89(6), 586-593. Author URL.
Wilson H, De Micco R, Niccolini F, Politis M (2017). Molecular imaging Markers to Track Huntington's Disease Pathology. FRONTIERS IN NEUROLOGY, 8 Author URL.
Strafella AP, Bohnen NI, Perlmutter JS, Eidelberg D, Pavese N, Van Eimeren T, Piccini P, Politis M, Thobois S, Ceravolo R, et al (2017). Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. MOVEMENT DISORDERS, 32(2), 181-192. Author URL.
Martin-Bastida A, Lao-Kaim NP, Loane C, Politis M, Roussakis AA, Valle-Guzman N, Kefalopoulou Z, Paul-Visse G, Widner H, Xing Y, et al (2017). Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility. European Journal of Neurology, 24(2), 357-365. Abstract.
Pagano G, Yousaf T, Politis M (2017). PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 17(11). Author URL.
Mehranian A, Belzunce MA, Niccolini F, Politis M, Prieto C, Turkheimer F, Hammers A, Reader AJ (2017). PET image reconstruction using multi-parametric anato-functional priors. PHYSICS IN MEDICINE AND BIOLOGY, 62(15), 5975-6007. Author URL.
Qamar MA, Sauerbier A, Politis M, Carr H, Loehrer P, Chaudhuri KR (2017). Presynaptic dopaminergic terminal imaging & non-motor symptoms assessment of Parkinson's disease: Evidence for dopaminergic basis?. Parkinson's Disease, 3(1). Abstract.
Pagano G, Niccolini F, Fusar-Poli P, Politis M (2017). Serotonin transporter in Parkinson's disease: a meta-analysis of positron emission tomography studies. ANNALS OF NEUROLOGY, 81(2), 171-180. Author URL.
Politis M, Sauerbier A, Loane C, Pavese N, Martin A, Corcoran B, Brooks DJ, Ray-Chaudhuri K, Piccini P (2017). Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. MOVEMENT DISORDERS, 32(2), 235-240. Author URL.
Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D (2017). The psychosis spectrum in Parkinson disease. Nat Rev Neurol, 13(2), 81-95. Abstract. Author URL.
Pagano G, Niccolini F, Yousaf T, Wilson H, Polychronis S, Chaudhuri KR, Politis M (2017). Urinary Dysfunction in Early De Novo Patients with Parkinson's Disease. MOVEMENT DISORDERS, 32(6), 939-940. Author URL.
Niccolini F, Politis M (2016). A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 43(12), 2244-2254. Author URL.
Loane C, Politis M, Kefalopoulou Z, Valle-Guzman N, Paul G, Widner H, Foltynie T, Barker RA, Piccini P (2016). Aberrant nigral diffusion in Parkinson's disease: a longitudinal diffusion tensor imaging study. MOVEMENT DISORDERS, 31(7), 1020-1026. Author URL.
Diggle CP, Sukoff Rizzo SJ, Popiolek M, Hinttala R, Schülke J-P, Kurian MA, Carr IM, Markham AF, Bonthron DT, Watson C, et al (2016). Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy. Am J Hum Genet, 98(4), 735-743. Abstract. Author URL.
Roy R, Niccolini F, Pagano G, Politis M (2016). Cholinergic imaging in dementia spectrum disorders. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 43(7), 1376-1386. Author URL.
Pagano G, Niccolini F, Politis M (2016). Current status of PET imaging in Huntington's disease. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 43(6), 1171-1182. Author URL.
Sauerbier A, Martinez-Martin P, Politis M, Rizos A, Trojanovic N, Mulholland N, Vivian G, Corcoran B, Trivedi D, Perkins L, et al (2016). Fatigue in Parkinson's disease and striatum dopamine transporter scan (DaTscan) uptake. Parkinsonism & Related Disorders, 22
Sauerbier A, Martinez-Martin P, Politis M, Rizos A, Trojanovic N, Mulholland N, Vivian G, Corcoran B, Trivedi D, Perkins L, et al (2016). Fatigue in Parkinson's disease and striatum dopamine transporter scan (DaTscan) uptake. Parkinsonism & Related Disorders, 22, e161-e162.
Pagano G, Niccolini F, Politis M (2016). Imaging in Parkinson's disease. CLINICAL MEDICINE, 16(4), 371-375. Author URL.
Wilson H, Niccolini F, Haider S, Marques TR, Pagano G, Coello C, Natesan S, Kapur S, Rabiner EA, Gunn RN, et al (2016). Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. JOURNAL OF THE NEUROLOGICAL SCIENCES, 368, 243-248. Author URL.
Politis M, Ashraghi M, Pagano G, Polychronis S, Niccolini F (2016). Parkinson’s Disease, Diabetes and Cognitive Impairment. Recent Patents on Endocrine Metabolic & Immune Drug Discovery, 10(999), 1-1.
Ashraghi MR, Pagano G, Polychronis S, Niccolini F, Politis M (2016). Parkinson’s disease, diabetes and cognitive impairment. Recent Patents on Endocrine, Metabolic and Immune Drug Discovery, 10(1), 11-21. Abstract.
Marques TR, Natesan S, Niccolini F, Politis M, Gunn RN, Searle GE, Howes O, Rabiner EA, Kapur S (2016). Phosphodiesterase 10A in Schizophrenia: a PET Study Using [<SUP>11</SUP>C]IMA107. AMERICAN JOURNAL OF PSYCHIATRY, 173(7), 714-721. Author URL.
Schrag A, Politis M (2016). Serotonergic loss underlying apathy in Parkinson's disease. BRAIN, 139, 2338-2339. Author URL.
Roussakis A-A, Politis M, Towey D, Piccini P (2016). Serotonin-to-dopamine transporter ratios in Parkinson disease Relevance for dyskinesias. NEUROLOGY, 86(12), 1152-1158. Author URL.
Niccolini F, Haider S, Marques TR, Muhlert N, Tziortzi AC, Searle GE, Natesan S, Piccini P, Kapur S, Rabiner EA, et al (2015). Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. BRAIN, 138, 3016-3029. Author URL.
Giannetti P, Politis M, Su P, Turkheimer FE, Malik O, Keihaninejad S, Wu K, Waldman A, Reynolds R, Nicholas R, et al (2015). Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. BRAIN, 138, 110-119. Author URL.
Politis M, Lahiri N, Niccolini F, Su P, Wu K, Giannetti P, Scahill RI, Turkheimer FE, Tabrizi SJ, Piccini P, et al (2015). Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. NEUROBIOLOGY OF DISEASE, 83, 115-121. Author URL.
Niccolini F, Foltynie T, Reis Marques T, Natesan S, Kapur S, Muhlert N, Tzortzi A, Rabiner E, Gunn R, Piccini P, et al (2015). Loss of phosphodiesterase 10A (PDE-10A) signalling is associated with progression and severity in patients with Parkinson’s disease (P6.081). Neurology, 84(14_supplement).
Niccolini F, Foltynie T, Marques TR, Muhlert N, Tziortzi AC, Searle GE, Natesan S, Kapur S, Rabiner EA, Gunn RN, et al (2015). Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. BRAIN, 138, 3003-3015. Author URL.
Niccolini F, Rocchi L, Politis M (2015). Molecular imaging of levodopa-induced dyskinesias. CELLULAR AND MOLECULAR LIFE SCIENCES, 72(11), 2107-2117. Author URL.
Pellicano C, Niccolini F, Wu K, O'Sullivan SS, Lawrence AD, Lees AJ, Piccini P, Politis M (2015). Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. JOURNAL OF NEUROLOGY, 262(12), 2653-2661. Author URL.
Antonio M-B, Politis M, Loane C, Nicholas L-K, Valle-Guzman N, Kefalopoulou Z, Paul G, Widner H, Foltynie T, Barker R, et al (2015). Motor Associations of Iron Deposition in Patients with Parkinson’s Disease (P6.065). Neurology, 84(14_supplement).
Niccolini F, Su P, Politis M (2015). PET in Multiple Sclerosis. CLINICAL NUCLEAR MEDICINE, 40(1), E46-E52. Author URL.
Roussakis A, Politis M, Towey D, Piccini P (2015). Parkinson’s disease progression is associated with increased putaminal serotonin to dopamine transporter ratio: relevance for dyskinesias (I3-1B). Neurology, 84(14_supplement).
Roussakis A, Politis M, Towey D, Piccini P (2015). Parkinson’s disease progression is associated with increased putaminal serotonin to dopamine transporter ratio: relevance for dyskinesias (S48.004). Neurology, 84(14_supplement).
Loane C, Wu K, O'Sullivan SS, Lawrence AD, Woodhead Z, Lees AJ, Piccini P, Politis M (2015). Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome. PARKINSONISM & RELATED DISORDERS, 21(11), 1336-1341. Author URL.
Rocchi L, Niccolini F, Politis M (2015). Recent imaging advances in neurology. JOURNAL OF NEUROLOGY, 262(9), 2182-2194. Author URL.
Politis M, Niccolini F (2015). Serotonin in Parkinson's disease. Behav Brain Res, 277, 136-145. Abstract. Author URL.
Wu K, Politis M, O'Sullivan SS, Lawrence AD, Warsi S, Bose S, Lees AJ, Piccini P (2015). Single versus multiple impulse control disorders in Parkinson's disease: an <SUP>11</SUP>C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. JOURNAL OF NEUROLOGY, 262(6), 1504-1514. Author URL.
Turkheimer FE, Bodini B, Politis M, Pariante CM, Ciccarelli O, Yeo RA (2015). The X-Linked Hypothesis of Brain Disorders: can Gender Ratios Tell Us Anything About Cellular Etiology of Neurodegenerative and Psychiatric Diseases?. NEUROSCIENTIST, 21(6), 589-598. Author URL.
Smith R, Wu K, Hart T, Loane C, Brooks DJ, Bjorklund A, Odin P, Piccini P, Politis M (2015). The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. NEUROBIOLOGY OF AGING, 36(4), 1736-1742. Author URL.
Niccolini F, Su P, Politis M (2014). Dopamine receptor mapping with PET imaging in Parkinson's disease. JOURNAL OF NEUROLOGY, 261(12), 2251-2263. Author URL.
Niccolini F, Loane C, Politis M (2014). Dyskinesias in Parkinson's disease: views from positron emission tomography studies. EUROPEAN JOURNAL OF NEUROLOGY, 21(5), 694-+. Author URL.
Garvey LJ, Pavese N, Politis M, Ramlackhansingh A, Brooks DJ, Taylor-Robinson SD, Winston A (2014). Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. AIDS, 28(1), 67-72. Author URL.
Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhatia K, Jahanshahi M, Widner H, Rehncrona S, Brundin P, Bjorklund A, et al (2014). Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease Two Case Reports. JAMA NEUROLOGY, 71(1), 83-87. Author URL.
Giannetti P, Politis M, Su P, Turkheimer F, Malik O, Keihaninejad S, Wu K, Reynolds R, Nicholas R, Piccini P, et al (2014). Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study. NEUROBIOLOGY OF DISEASE, 65, 203-210. Author URL.
Niccolini F, Politis M (2014). Neuroimaging in Huntington's disease. World J Radiol, 6(6), 301-312. Abstract. Author URL.
Politis M (2014). Neuroimaging in Parkinson disease: from research setting to clinical practice. NATURE REVIEWS NEUROLOGY, 10(12), 708-722. Author URL.
Wu K, Politis M, O'Sullivan SS, Lawrence AD, Warsi S, Lees A, Piccini P (2014). Problematic Internet use in Parkinson's disease. PARKINSONISM & RELATED DISORDERS, 20(5), 482-487. Author URL.
Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, Bain P, Molloy S, Piccini P (2014). Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. JOURNAL OF CLINICAL INVESTIGATION, 124(3), 1340-1349. Author URL.
Loane C, Pilinis C, Lekkas TD, Politis M (2013). Ambient particulate matter and its potential neurological consequences. REVIEWS IN THE NEUROSCIENCES, 24(3), 323-335. Author URL.
Roussakis A-A, Piccini P, Politis M (2013). Clinical utility of DaTscan™ (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes. Degener Neurol Neuromuscul Dis, 3, 33-39. Abstract. Author URL.
O'Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, Bose SK, Djamshidian A, Lees AJ, Piccini P (2013). Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours (vol 134, pg 969, 2011). BRAIN, 136, 985-985. Author URL.
Politis M, Loane C, Wu K, O'Sullivan SS, Woodhead Z, Kiferle L, Lawrence AD, Lees AJ, Piccini P (2013). Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. BRAIN, 136, 400-411. Author URL.
Loane C, Wu K, Bain P, Brooks DJ, Piccini P, Politis M (2013). Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. NEUROLOGY, 80(20), 1850-1855. Author URL.
Garvey LJ, Pavese N, Ramlackhansingh A, Thomson E, Allsop JM, Politis M, Kulasegaram R, Main J, Brooks DJ, Taylor-Robinson SD, et al (2012). Acute HCV/HIV Coinfection is Associated with Cognitive Dysfunction and Cerebral Metabolite Disturbance, but Not Increased Microglial Cell Activation. PLOS ONE, 7(7). Author URL.
Loane C, Politis M (2012). Buspirone: What is it all about?. BRAIN RESEARCH, 1461, 111-118. Author URL.
Politis M, Lindvall O (2012). Clinical application of stem cell therapy in Parkinson's disease. BMC MEDICINE, 10 Author URL.
Politis M, Su P, Piccini P (2012). Imaging of microglia in patients with neurodegenerative disorders. FRONTIERS IN PHARMACOLOGY, 3 Author URL.
Wu K, Politis M, Piccini P (2012). Impulse control disorders in parkinson's disease: a review. Current Psychiatry Reviews, 8(3), 235-246. Abstract.
Politis M, Giannetti P, Su P, Turkheimer F, Keihaninejad S, Wu K, Waldman A, Malik O, Matthews PM, Reynolds R, et al (2012). Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. NEUROLOGY, 79(6), 523-530. Author URL.
Politis M, Piccini P (2012). Positron emission tomography imaging in neurological disorders. JOURNAL OF NEUROLOGY, 259(9), 1769-1780. Author URL.
Politis M, Loane C (2012). Reduplicative Paramnesia: a Review. PSYCHOPATHOLOGY, 45(6), 337-343. Author URL.
Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, Bjorklund A, Lindvall O, Piccini P (2012). Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinson's Patients Treated with Dopamine Grafts. SCIENCE TRANSLATIONAL MEDICINE, 4(128). Author URL.
Wu K, O'Keeffe D, Politis M, O'Keeffe GC, Robbins TW, Bose SK, Brooks DJ, Piccini P, Barker RA (2012). The catechol-O-methyltransferase Val<SUP>158</SUP>Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. BRAIN, 135, 2449-2457. Author URL.
O'Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, Bose SK, Djamshidian A, Lees AJ, Piccini P (2011). Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. BRAIN, 134, 969-978. Author URL.
Loane C, Su P, Politis M (2011). Different dyskinesias in Parkinson's disease and their relationship to levodopa. European Neurological Journal, 3(1), 20-26. Abstract.
Politis M, Oertel WH, Wu K, Quinn NP, Pogarell O, Brooks DJ, Bjorklund A, Lindvall O, Piccini P (2011). Graft-Induced Dyskinesias in Parkinson's Disease: High Striatal Serotonin/Dopamine Transporter Ratio. MOVEMENT DISORDERS, 26(11), 1997-2003. Author URL.
Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, Tabrizi SJ, Barker RA, Piccini P (2011). Microglial activation in regions related to cognitive function predicts disease onset in Huntington's Disease: a multimodal imaging study. HUMAN BRAIN MAPPING, 32(2), 258-270. Author URL.
Politis M (2011). Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease. BMC MEDICINE, 9 Author URL.
Kiferle L, Politis M, Muraro PA, Piccini P (2011). Positron emission tomography imaging in multiple sclerosis-current status and future applications. EUROPEAN JOURNAL OF NEUROLOGY, 18(2), 226-231. Author URL.
Loane C, Politis M (2011). Positron emission tomography neuroimaging in Parkinson's disease. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 3(4), 323-341. Author URL.
Politis M, Loane C (2011). Serotonergic Dysfunction in Parkinson's Disease and its Relevance to Disability. THESCIENTIFICWORLDJOURNAL, 11, 1726-1734. Author URL.
Politis M, Loane C, Wu K, Brooks DJ, Piccini P (2011). Serotonergic mediated body mass index changes in Parkinson's disease. NEUROBIOLOGY OF DISEASE, 43(3), 609-615. Author URL.
Su P, Loane C, Politis M (2011). The Use of Stem Cells in the Treatment of Parkinsons Disease. Insciences Journal, 136-156.
Politis M, Piccini P (2010). Brain imaging after neural transplantation. Prog Brain Res, 184, 193-203. Abstract. Author URL.
Pavese N, Politis M, Tai YF, Barker RA, Tabrizi SJ, Mason SL, Brooks DJ, Piccini P (2010). Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. NEUROBIOLOGY OF DISEASE, 37(2), 356-361. Author URL.
Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, Piccini P (2010). Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. NEUROLOGY, 75(21), 1920-1927. Author URL.
Politis M (2010). Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?. BMC MEDICINE, 8 Author URL.
Politis M, Wu K, Molloy S, Bain PG, Chaudhuri KR, Piccini P (2010). Parkinson's Disease Symptoms: the Patient's Perspective. MOVEMENT DISORDERS, 25(11), 1646-1651. Author URL.
Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, Bjorklund A, Lindvall O, Piccini P (2010). Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson's Patients with Neural Transplants. SCIENCE TRANSLATIONAL MEDICINE, 2(38). Author URL.
Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, Piccini P (2010). Staging of serotonergic dysfunction in Parkinson's Disease: an <i>in vivo</i> <SUP>11</SUP>C-DASB PET study. NEUROBIOLOGY OF DISEASE, 40(1), 216-221. Author URL.
Wu K, Politis M, Piccini P (2009). Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management. POSTGRADUATE MEDICAL JOURNAL, 85(1009), 590-596. Author URL.
Politis M, Wu K, Piccini P (2009). Positron emission tomography imaging in Parkinson's disease. Minerva Psichiatrica, 50(1), 55-78. Abstract.
Politis M, Piccini P, Pavese N, Koh S-B, Brooks DJ (2008). Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an <i>in vivo</i> <SUP>11</SUP>C-raclopride PET study. EXPERIMENTAL NEUROLOGY, 214(1), 112-116. Author URL.
Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P (2008). Hypothalamic involvement in Huntingtons disease: an <i>in vivo</i> PET study. BRAIN, 131, 2860-2869. Author URL.
Politis M, Pilinis C, Lekkas TD (2008). ULTRAFINE PARTICLES (UFP) AND HEALTH EFFECTS. DANGEROUS. LIKE NO OTHER PM? REVIEW AND ANALYSIS. GLOBAL NEST JOURNAL, 10(3), 439-452. Author URL.
Chapters
de Natale ER, Wilson H, Politis M (2023). Chapter 1 Parkinson's disease and related disorders the pursuit for reliable readouts and the role of neuroimaging. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 3-19.
Tondo G, Comi C, Naldi A, de Natale ER, Politis M (2023). Chapter 12 Neuroimaging in multiple system atrophy. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 311-354.
de Natale ER, Wilson H, Politis M, Niccolini F (2023). Chapter 13 Neuroimaging in progressive supranuclear palsy. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 355-397.
Wilson H, de Natale ER, Politis M, Niccolini F (2023). Chapter 14 Neuroimaging in corticobasal syndrome. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 399-417.
de Natale ER, Wilson H, Niccolini F, Politis M (2023). Chapter 15 Molecular imaging in Huntington's disease. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 421-448.
Belogianni C, Wilson H, de Natale ER, Politis M (2023). Chapter 16 Magnetic resonance imaging in Huntington's disease. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 449-489.
Terry A, de Natale ER, Politis M (2023). Chapter 17 Neuroimaging in essential tremor. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 491-518.
de Natale ER, Wilson H, Udeh-Momoh C, Ford JK, Politis M, Middleton LT (2023). Chapter 18 How molecular imaging studies can disentangle disease mechanisms in age-related neurodegenerative disorders. In (Ed) Aging, Elsevier, 455-492.
de Natale ER, Wilson H, Politis M (2023). Chapter 18 Neuroimaging of restless legs syndrome. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 519-540.
Terry A, de Natale Rosario E, Politis M (2023). Chapter 19 Neuroimaging in dystonia. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 541-566.
Wilson H, de Natale ER, Politis M (2023). Chapter 2 Advances in magnetic resonance imaging. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 21-52.
Wilson H, Politis M (2023). Chapter 3 Advances in molecular neuroimaging methodology. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 53-66.
de Natale ER, Wilson H, Politis M (2023). Chapter 4 Dopaminergic molecular imaging in familial and idiopathic Parkinson's disease. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 69-104.
Wilson H, Terry A, Politis M (2023). Chapter 6 Molecular imaging beyond dopamine and serotonin in familial and idiopathic Parkinson’s disease. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 121-150.
Verghese JP, de Natale ER, Politis M (2023). Chapter 7 Structural MRI in familial and idiopathic PD. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 151-199.
Verghese JP, de Natale ER, Politis M (2023). Chapter 8 Functional MRI in familial and idiopathic PD. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 201-250.
de Natale ER, Verghese JP, Wilson H, Politis M (2023). Chapter 9 Molecular imaging in prodromal Parkinson’s disease. In (Ed) Neuroimaging in Parkinson�s Disease and Related Disorders, Elsevier, 251-272.
De Natale ER, Wilson H, Politis M (2021). Imaging BiomarkersBiomarkers in Huntington’s DiseaseHuntington’s disease (HD). In (Ed) Neurodegenerative Diseases Biomarkers, Springer Nature, 457-505.
Wilson H, de Natale ER, Politis M (2021). Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson's disease. In (Ed) Handbook of Clinical Neurology, 189-205. Abstract.
de Natale ER, Wilson H, Politis M (2021). Serotonergic imaging in Parkinson's disease. In (Ed) Progress in Brain Research, 303-338. Abstract.
Tondo G, Esposito M, Dervenoulas G, Wilson H, Politis M, Pagano G (2019). Hybrid PET-MRI Applications in Movement Disorders. In (Ed) International Review of Neurobiology, 211-257. Abstract.
Cousins O, Yousaf T, Wilson H, Pagano G, Politis M (2019). Molecular Imaging of Dementia with Lewy Bodies. In (Ed) International Review of Neurobiology, 59-93. Abstract.
Yousaf T, Dervenoulas G, Politis M (2018). Advances in MRI Methodology. In (Ed) IMAGING IN MOVEMENT DISORDERS: IMAGING METHODOLOGY AND APPLICATIONS IN PARKINSON'S DISEASE, 31-76. Author URL.
de Natale ER, Wilson H, Pagano G, Politis M (2018). Imaging Transplantation in Movement Disorders. In (Ed) IMAGING IN MOVEMENT DISORDERS: IMAGING APPLICATIONS IN NON-PARKINSONIAN AND OTHER MOVEMENT DISORDERS, 213-263. Author URL.
Politis M (2018). Imaging in Movement Disorders: Imaging Applications in NonParkinsonian and Other Movement Disorders PREFACE. In (Ed) IMAGING IN MOVEMENT DISORDERS: IMAGING APPLICATIONS IN NON-PARKINSONIAN AND OTHER MOVEMENT DISORDERS, IX-X. Author URL.
Politis M (2018). Imaging in Movement Disorders: Imaging Methodology and Applications in Parkinson's Disease PREFACE. In (Ed) IMAGING IN MOVEMENT DISORDERS: IMAGING METHODOLOGY AND APPLICATIONS IN PARKINSON'S DISEASE, XV-XVI. Author URL.
Politis M (2018). Imaging in Movement Disorders: Imaging in Atypical Parkinsonism and Familial Movement Disorders PREFACE. In (Ed) IMAGING IN MOVEMENT DISORDERS: IMAGING IN ATYPICAL PARKINSONISM AND FAMILIAL MOVEMENT DISORDERS, XI-XII. Author URL.
Wilson H, Politis M (2018). Molecular Imaging in Huntington's Disease. In (Ed) IMAGING IN MOVEMENT DISORDERS: IMAGING IN ATYPICAL PARKINSONISM AND FAMILIAL MOVEMENT DISORDERS, 289-333. Author URL.
de Natale ER, Niccolini F, Wilson H, Politis M (2018). Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease. In (Ed) IMAGING IN MOVEMENT DISORDERS: IMAGING METHODOLOGY AND APPLICATIONS IN PARKINSON'S DISEASE, 131-172. Author URL.
Pagano G, Politis M (2018). Molecular Imaging of the Serotonergic System in Parkinson's Disease. In (Ed) IMAGING IN MOVEMENT DISORDERS: IMAGING METHODOLOGY AND APPLICATIONS IN PARKINSON'S DISEASE, 173-210. Author URL.
Wilson H, Dervenoulas G, Politis M (2018). Structural Magnetic Resonance Imaging in Huntington's Disease. In (Ed) IMAGING IN MOVEMENT DISORDERS: IMAGING IN ATYPICAL PARKINSONISM AND FAMILIAL MOVEMENT DISORDERS, 335-380. Author URL.
Politis M, Pagano G, Niccolini F (2017). Imaging in Parkinson's Disease. In (Ed) PARKINSON'S DISEASE, 233-274. Author URL.
Yousaf T, Wilson H, Politis M (2017). Imaging the Nonmotor Symptoms in Parkinson's Disease. In (Ed) NONMOTOR PARKINSON'S: THE HIDDEN FACE: THE MANY HIDDEN FACES, 179-257. Author URL.
Politis M, Piccini P (2012). <i>In vivo</i> imaging of the integration and function of nigral grafts in clinical trials. In (Ed) FUNCTIONAL NEURAL TRANSPLANTATION III PRIMARY AND STEM CELL THERAPIES FOR BRAIN REPAIR, PT I, 199-220. Author URL.
Su P, Politis M (2012). The role of microglia in neurodegenerative disease. In (Ed) Microglia: Biology, Functions and Roles in Disease, 93-117. Abstract.
Piccini P, Politis M (2011). Cell-Based Therapies. In (Ed) Imaging in Parkinson's Disease. Abstract.
Politis M, Loane C (2011). Imaging Dyskinesias in Parkinson’s Disease. In (Ed) Diagnosis and Treatment of Parkinson's Disease, IntechOpen.
Conferences
van Wamelen D, Politis M, Aarsland D, Odin P, van Laar T, Henriksen T, Corcoran B, Vivian G, Parry M, Mulholland N, et al (2019). APOmorphine infusion and aMYLoid deposition in Parkinson's disease (APOMYL): preliminary clinical and amyloid imaging data. Author URL.
van Wamelen D, Politis M, Aarsland D, Odin P, van Laar T, Henriksen T, Corcoran B, Vivian G, Wilson H, Parry M, et al (2019). APOmorphine infusion and aMYLoid deposition in Parkinson's disease (APOMYL): preliminary clinical and amyloid imaging data. Author URL.
Chandra A, Farrell C, Wilson H, Dervenoulas G, De Natale E, Politis M (2019). Aquaporin-4 genetic variation is associated with disease stage progression and pathology in patients with Alzheimer's disease. Author URL.
Caminiti SP, Pagano G, Dervenoulas G, Yousaf T, Wilson H, Politis M (2019). Arterial spin labelling detects striatal hypoperfusion in early drug-naive patients with Parkinson's disease. Author URL.
Caminiti SP, Pagano G, Dervenoulas G, Yousaf T, Wilson H, Politis M (2019). Arterial spin labelling detects subcortical hypoperfusion in early drug-naive patients with Parkinson's disease. Author URL.
Yousaf T, Pagano G, Wilson H, Corcoran B, Vivian G, Politis M (2019). Comparison between [11C]PE2I PET and [123I]FP-CIT SPECT as markers of DAT expression in early Parkinson's disease. Author URL.
Pagano G, Wilson H, Yousaf T, Niccolini F, Khan N, Martino D, Gunn R, Rabiner E, Piccini P, Foltynie T, et al (2019). Comparison of PDE10A and DAT expression as markers of disease burden in early Parkinson's disease. Author URL.
Pagano G, Wilson H, Yousaf T, Niccolini F, Khan N, Martino D, Gunn R, Rabiner E, Piccini P, Foltynie T, et al (2019). Comparison of PDE10A and DAT expression as markers of disease burden in early Parkinson's disease. Author URL.
De Natale ER, Caminiti SP, Chappell Z, Yousaf T, Wilson H, Politis M (2019). Connectivity alterations in dopaminergic and cholinergic networks mediate cognitive performance in patients with Parkinson's disease: a resting-state fMRI study. Author URL.
de Natale ER, Caminiti SP, Chappell Z, Yousaf T, Wilson H, Politis M (2019). Connectivity alterations in dopaminergic and cholinergic networks mediate cognitive performance in patients with Parkinson's disease: a resting-state fMRI study. Author URL.
Farrell C, Pagano G, De Natale E, Politis M (2019). Depressive Symptoms are Associated with Lower Locus Coeruleus Volumes in Parkinson's disease. Author URL.
Farrell C, Pagano G, de Natale E, Politis M (2019). Depressive symptoms are associated with lower locus coeruleus volumes in Parkinson's disease. Author URL.
Carotenuto A, Giordano B, Dervenoulas G, Wilson H, Veronese M, Chappell Z, Polychronis S, Mackewn J, Turkheimer F, Williams SC, et al (2019). Direct comparison between T1/T2-weighted ratio MRI and [18F] florbetaben PET imaging as measures of myelin integrity in multiple sclerosis. Author URL.
Contreras VS, Tayyabah Y, Caminiti S, Politis M (2019). Drooling in Parkinson's Disease: a [123I]FP-CIT SPECT study. Author URL.
Contreras VCS, Tayyabah Y, Caminiti S, Politis M (2019). Drooling in Parkinson's disease: an [123I] FP-CIT SPECT study. Author URL.
Schubert JJ, Veronese M, Bodini B, Tonietto M, Stankoff B, Martin-Bastida A, Politis M, Piccini P, Turkheimer FE (2019). Dynamic PET with 11C-and 18F-tracers for measuring cerebrospinal fluid alterations in multiple sclerosis. Author URL.
Wilson H, Niccolini F, Dervenoulas G, Tyacke R, Myers J, Gunn R, Nutt D, Rabiner E, Tabrizi S, Politis M, et al (2019). Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Huntington's Disease: an in vivo [11C]BU99008 PET study. Author URL.
Wilson H, Dervenoulas G, Pagano G, Tyacke R, Myers J, Gunn R, Rabiner E, Nutt D, Politis M (2019). Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's Disease: an in vivo [11C]BU99008 PET study. Author URL.
Wilson H, Dervenoulas G, Pagano G, Tyacke R, Myers J, Gunn R, Rabiner E, Nutt DJ, Politis M (2019). Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo [11C] BU99008 PET study. Author URL.
Wilson H, Niccolini F, Dervenoulas G, Tyacke R, Myers J, Gunn R, Nutt DJ, Rabiner E, Tabrizi SJ, Politis M, et al (2019). Evaluation of imidazoline 2 binding sites reflecting astroglia pathology in Huntington's disease: an in vivo [11C] BU99008 PET study. Author URL.
Caminiti SP, Chappell Z, Carotenuto A, Dervenoulas G, Yousaf T, Pagano G, Wilson H, Politis M (2019). Evidence of altered Serotonergic Network in Parkinson's disease by using a multi-modal MRI and PET imaging approach. Author URL.
Caminiti SP, Chappell Z, Carotenuto A, Dervenoulas G, Yousaf T, Pagano G, Wilson H, Politis M (2019). Evidence of altered Serotonergic Network in Parkinson's disease by using a multimodal MRI and PET imaging approach. Author URL.
Yousaf T, Dervenoulos G, Pagano G, Loane C, Wilson H, Chandra A, Cousins O, Gunn R, Rabiner E, Niccolini F, et al (2019). Functional connectivity and microstructural alterations in regions of synaptic density loss in DLB and PDD. Author URL.
Yousaf T, Dervenoulas G, Pagano G, Loane C, Wilson H, Chandra A, Cousins O, Gunn R, Rabiner E, Niccolini F, et al (2019). Functional connectivity and microstructural alterations in regions of synaptic density loss in DLB and PDD. Author URL.
Contreras VS, Tayyabah Y, Caminiti S, Politis M (2019). Gait impairment in Parkinson's Disease: an [123I]FP-CIT SPECT study. Author URL.
Contreras VCS, Tayyabah Y, Caminiti SP, Politis M (2019). Gait impairment in Parkinson's disease: an [123I]FP-CIT SPECT study. Author URL.
Chandra A, Pagano G, Yousaf T, Wilson H, Politis M (2019). Imaging Parkinson's disease pathology: a comparison between neuromelanin-sensitive MRI, susceptibility weighted imaging and [11C]PE2I DAT PET. Author URL.
Carotenuto A, Wilson H, Giordano B, Caminiti S, Chappell Z, Dervenoulas G, Williams SC, Hammers A, Silber E, Brex PA, et al (2019). Impairment of neurotransmitter networks in patients with Multiple Sclerosis: Clinical implications. Author URL.
Carotenuto A, Wilson H, Giordano B, Chappell Z, Dervenoulas G, Williams SC, Hammers A, Silber E, Brex PA, Politis M, et al (2019). In vivo evaluation of Multiple Sclerosis pathology with combined perfusion and diffusion MR imaging. Author URL.
Rota S, Yousaf T, Wilson H, Dervenoulas G, Pagano G, Aarsland D, Politis M (2019). In vivo increased striatal iron deposition in Parkinson's Disease Dementia and Dementia with Lewy Body. Author URL.
Rota S, Yousaf T, Wilson H, Dervenoulas G, Pagano G, Aarsland D, Politis M (2019). In vivo increased striatal iron deposition in Parkinson's disease dementia and dementia with Lewy body. Author URL.
Chandra A, Farrell C, Wilson H, De Natale E, Politis M (2019). LRP1 genetic variation is associated with disease stage progression and pathology in patients with Alzheimer's disease. Author URL.
Chappell Z, Yousaf T, Wilson H, Politis M (2019). Longitudinal Microstructural Changes in Mild Cognitive Impairment. Author URL.
Esposito M, Yousaf T, Wilson H, Peluso S, Santoro L, Manganelli F, Pagano G, Politis M (2019). Microstructural Changes in Basal Ganglia and Cerebellar Networks in Patients with Idiopathic Blepharospasm. Author URL.
Pagano G, Wilson H, Mansur A, Caminiti S, Comley R, Tsukada H, Gunn R, Rabiner E, Politis M (2019). Mitochondrial Complex 1, Sigma 1 Receptor and Synaptic Vesicle protein 2A density in early de novo patients with Parkinson's Disease: pilot PET data. Author URL.
Pagano G, Wilson H, Mansur A, Caminiti SP, Comley R, Tsukada H, Gunn R, Rabiner E, Politis M (2019). Mitochondrial complex 1, sigma 1 receptor and synaptic vesicle protein 2A density in early de novo patients with Parkinson's disease: pilot PET data. Author URL.
Chappell Z, Wilson H, Politis M (2019). Motor Networks in Tremor-Dominant Parkinson's Disease. A resting-state functional MRI and diffusion tensor imaging analysis. Author URL.
Cousins O, Wilson H, Yousaf T, Caminiti SP, Politis M (2019). Neuroanatomical and clinical predictors of pain in patients with early de novo Parkinson's disease. Author URL.
Cousins O, Wilson H, Yousaf T, Caminiti S, Politis M (2019). Neuroanatomical and clinical predictors of pain in patients with early de novo Parkinson's disease. Author URL.
Cousins O, Pagano G, Belogianni C, Politis M (2019). Neuroanatomical changes in hypertensive patients may underlie increased risk of cognitive impairment. Author URL.
de Natale ER, Wilson H, Dervenoulas G, Niccolini F, Tabrizi SJ, Politis M (2019). Neuromelanin MRI detects monoaminergic cell loss in Huntington Disease Expansion Gene Carriers. Author URL.
De Natale ER, Wilson H, Dervenoulas G, Niccolini F, Tabrizi SJ, Politis M (2019). Neuromelanin MRI detects monoaminergic cell loss in Huntington disease expansion gene carriers. Author URL.
Polychronis S, Pagano G, Contreras VCS, Yousaf T, Politis M (2019). Neuronal Network Underlying Dysphagia in Parkinson's Disease. Author URL.
Polychronis S, Pagano G, Contreras VCS, Yousaf T, Politis M (2019). Neuronal Network Underlying Speech Difficulties in Parkinson's Disease. Author URL.
Polychronis S, Pagano G, Contreras VCS, Yousaf T, Politis M (2019). Neuronal networks underlying dysphagia in Parkinson's disease. Author URL.
Polychronis S, Pagano G, Contreras VCS, Yousaf T, Politis M (2019). Neuronal networks underlying speech difficulties in Parkinson's disease. Author URL.
Chappell Z, Pagano G, Wilson H, Niccolini F, Gunn R, Rabiner E, Foltynie T, Politis M (2019). Phosphodiesterase 10A and cognition in Parkinson's disease. Author URL.
Chappell Z, Pagano G, Wilson H, Niccolini F, Gunn R, Rabiner E, Foltynie T, Politis M (2019). Phosphodiesterase 10A and cognition in Parkinson's disease. Author URL.
Tagliente S, Wilson H, Chappell Z, Yousaf T, De Natale E, Pagano G, Politis M (2019). Probabilistic tractography study of the nigrostriatal pathway in Parkinson's disease. Author URL.
de Natale ER, Wilson H, Dervenoulas G, Niccolini F, Tabrizi SJ, Politis M (2019). Quantification of regional iron content with Susceptibility Weighted Imaging in Huntington Disease Expansion Gene Carriers. Author URL.
De Natale ER, Wilson H, Dervenoulas G, Niccolini F, Tabrizi SJ, Politis M (2019). Quantification of regional iron content with susceptibility weighted imaging in huntington disease expansion gene carriers. Author URL.
Cousins O, Pagano G, Schulz J, Dervenoulas G, Wilson H, Caminiti S, Polychronis S, Politis M (2019). Semantic fluency impairment and amygdala atrophy are predictive factors for the development of Parkinson's disease dementia. Author URL.
Cousins O, Pagano G, Schulz J, Dervenoulas G, Wilson H, Caminiti SP, Polychronis S, Politis M (2019). Semantic fluency impairment and amygdala atrophy are predictive factors for the development of Parkinson's disease dementia. Author URL.
Yousaf T, Kershaw M, Contreras VCS, Pagano G, Vickers P, Politis M (2019). Structural changes in non-manifesting GBA mutation carriers and GBA mutation carriers with Parkinson's disease. Author URL.
Yousaf T, Kershaw M, Contreras VS, Vickers P, Pagano G, Politis M (2019). Structural changes in non-manifesting GBA mutation carriers and GBA mutation carriers with Parkinson's disease. Author URL.
Pagano G, Vickers P, Schulz J, Wilson H, Politis M (2019). Structural connectivity changes in G2019S-LRRK2 gene mutation carriers without manifest Parkinson's disease. Author URL.
Pagano G, Vickers P, Schulz J, Wilson H, Politis M (2019). Structural connectivity changes in G2019S-LRRK2 gene mutation carriers without manifest Parkinson's disease. Author URL.
Contreras VS, Pagano G, Bonfante JF, Wilson H, Politis M (2019). Structural connectivity changes in prodromal Parkinson's disease patients: a multimodal MRI study. Author URL.
Contreras VCS, Pagano G, Bonfante JAF, Wilson H, Politis M (2019). Structural connectivity changes in prodromal Parkinson's disease patients: a multimodal MRI study. Author URL.
Schulz J, Yousaf T, Oshodin J, Politis M (2019). TOMM40 polymorphism is associated with cerebral β-amyloid load and clinical pathology in Alzheimer's disease dementia. Author URL.
Chandra A, Cousins O, Politis M (2019). The pathophysiological and clinical significance of soluable TREM2 in Mild Cognitive Impairment and Mild Alzheimer's disease. Author URL.
Acampora R, Chandra A, Farrell C, Wilson H, Dervenoulas G, De Natale E, Politis M (2019). The role of MAPT single nucleotide polymorphisms in the clinical phenotype of Alzheimer's disease. Author URL.
Wilson H, Dervenoulas G, Pagano G, Chandra A, Niccolini F, Esposito M, Gunn R, Ricciardi L, Rabiner E, Aarsland D, et al (2019). The role of Synaptic vesicle protein 2A (SV2A) in patients with Parkinson's disease dementia and Dementia with Lewy bodies: an in vivo [11C]UCB-J PET study. Author URL.
Yousaf T, Rajendran L, Politis M (2019). The role of hyperlipidemia in mild cognitive impairment and Alzheimer's disease. Author URL.
Wilson H, Dervenoulas G, Pagano G, Chandra A, Niccolini F, Esposito M, Gunn R, Ricciardi L, Rabiner E, Aarsland D, et al (2019). The role of synaptic vesicle protein 2A (SV2A) in patients with Parkinson's disease dementia and dementia with Lewy bodies: an in vivo [11C]UCB-J PET study. Author URL.
Farrell C, Yousaf T, Politis M (2019). Treating Depression in Parkinson's Disease: a Systematic Literature Review. Author URL.
Carotenuto A, Giordano B, Dervenoulas G, Wilson H, Veronese M, Chappell Z, Polychronis S, Niccolini F, MacKewn J, Turkheimer FE, et al (2018). <i>In vivo</i> assessment of myelin breakdown pattern in multiple sclerosis: a hybrid PET/MR [18F] florbetaben study. Author URL.
Carotenuto A, Giordano B, Dervenoulas G, Wilson H, Veronese M, Chappell Z, Polychronis S, Pagano G, MacKewn J, Turkheimer FE, et al (2018). A hybrid [<SUP>18</SUP>F]florbetapir-PET/MR imaging study to assess <i>in vivo</i> demyelination in multiple sclerosis. Author URL.
Carotenuto A, Wilson H, Giordano B, Chappell Z, Dervenoulas G, Williams SCR, Hammers A, Silber E, Brex PA, Politis M, et al (2018). In vivo evaluation of multiple sclerosis pathology with combined perfusion and diffusion MR imaging. Author URL.
Li W, Lao-Kaim N, Roussakis A, Martin-Bastida A, Valle-Guzman N, Loane C, Kefalopoulou Z, Politis M, Foltynie T, Barker R, et al (2017). 11C-PE2I and 18F-DOPA PET imaging for assessing the severity and rate of progression in Parkinson's disease: the longitudinal study. Author URL.
Pagano G, Niccolini F, Wilson H, Yousaf T, Khan N, Martino D, Gunn R, Rabiner E, Politis M (2017). Altered PDE10A expression detectable early in untreated Parkinson's disease patients. Author URL.
Pagano G, Niccolini F, Wilson H, Yousaf T, Khan N, Martino D, Gunn R, Rabiner E, Politis M (2017). Altered Pde10a Expression Detectable Early in Untreated Parkinson's Disease Patients. Author URL.
Bastida AM, Lao-Kaim NP, Xing Y, Loane C, Roussakis A, Schwarz ST, Li X, Valle-Guzman N, Mahlknecht P, Paul-Visse G, et al (2017). Assessing longitudinal iron deposition in deep grey matter nuclei with high-pass filtered phase MR Imaging in Parkinson's disease. Author URL.
Noyce A, Dickson J, Bestwick J, Isaias I, Politis M, Giovannoni G, Warner T, Lees A, Schrag A (2017). Associations of DAT SPECT and TCS with prodromal features of Parkinson's disease: Results in PREDICT-PD participants. Author URL.
Niccolini F, Diamantopoulos K, Kiosses S, Politis M (2017). Be vigilant for dementia in Parkinson's disease.
Pagano G, Polychronis S, Wilson H, Niccolini F, Politis M (2017). Diabetes mellitus and Parkinson's disease. Author URL.
Pagano G, Polychronis S, Wilson H, Niccolini F, Politis M (2017). Diabetes mellitus and Parkinson's disease. Author URL.
Martin-Bastida A, Lao-Kaim N, Xing Y, Loane C, Roussakis A, Schwarz S, Valle-Guzman N, Mahlknecht P, Li X, Paul-Visse G, et al (2017). High-Pass Filtered Phase Mr Imaging to Detect Longitudinal Motor Associations of Iron Accumulation in Parkinson's Disease. Author URL.
Giordano B, Pagano G, Hood J, Ferrara N, Politis M (2017). Hypertension and Parkinson's disease. Author URL.
Giordano B, Pagano G, Hood J, Ferrara N, Politis M (2017). Hypertension and Parkinson's disease. Author URL.
Dervenoulas G, Pagano G, Niccolini F, Giordano B, Politis M (2017). Hypertension linked to Alzheimer's pathology. Author URL.
Dervenoulas G, Pagano G, Niccolini F, Politis M (2017). IGF-1 levels are associated with CSF pathology and executive dysfunction in de novo Parkinson's disease patients. Author URL.
Dervenoulas G, Pagano G, Niccolini F, Politis M (2017). IGF-1 levels are associated with CSF pathology and executive dysfunction in de novo Parkinson's disease patients. Author URL.
Niccolini F, Wilson H, Hirschbichler S, Pagano G, Erro R, Yousaf T, Whittington A, Holton J, Martino D, Rabiner E, et al (2017). In vivo evaluation of tau and amyloid pathology in Corticobasal Syndrome. Author URL.
Wilson H, Niccolini F, Hirschbichler S, Pagano G, Erro R, Yousaf T, Whittington A, Gunn R, Rabiner E, Bhatia K, et al (2017). In vivo tau and amyloid pathology in Corticobasal Degeneration (CBD). Author URL.
Niccolini F, Wilson H, Hirschbichler S, Pagano G, Erro R, Yousaf T, Whittington A, Holton J, Martino D, Rabiner E, et al (2017). In-vivo evaluation of tau and amyloid pathology in Corticobasal Syndrome. Author URL.
Li W, Lao-Kaim N, Roussakis A-A, Martin-Bastida A, Loane C, Valle-Guzman N, Kefalopoulou Z, Politis M, Foltynie T, Barker R, et al (2017). Longitudinal comparison of 11C-PE2I and 18F-DOPA PET for assessing severity and rate of disease progression in patients with Parkinson's disease. Author URL.
Li W, Lao-Kaim NP, Roussakis A, Martin-Bastida A, Loane C, Valle-Guzman N, Kefalopoulou Z, Politis M, Foltynie T, Barker RA, et al (2017). Longitudinal comparison of 11C-PE2I and 18F-DOPA pet for assessing severity and rate of disease progression in patients with Parkinson's disease. Author URL.
Niccolini F, Mencacci NE, Rabiner E, Salpietro V, Pagano G, Balint B, Houlden H, Gunn R, Wood NW, Bhatia KP, et al (2017). Loss of PDE10A expression in patients with PDE10A and ADYC5 mutations. Author URL.
Niccolini F, Mencacci N, Rabiner E, Salpietro V, Pagano G, Balint B, Houlden H, Gunn R, Wood N, Bhatia K, et al (2017). Loss of PDE10A expression in patients with PDE10A and ADYC5 mutations. Author URL.
Bonfante JAF, Pagano G, Politis M (2017). Neuroimaging studies in familial forms of Parkinson's disease: a systematic review. Author URL.
Bonfante JF, Pagano G, Politis M (2017). Neuroimaging studies in familial forms of Parkinson's disease: a systematic review. Author URL.
Niccolini F, Wilson H, Giordano B, Diamantopoulos K, Pagano G, Chaudhuri KR, Politis M (2017). Non-motor symptom burden is associated with thalamic atrophy in Parkinson's disease. Author URL.
Niccolini F, Wilson H, Giordano B, Diamantopoulos K, Pagano G, Chaudhuri KR, Politis M (2017). Non-motor symptom burden is associated with thalamic atrophy in Parkinson's disease. Author URL.
Niccolini F, Wilson H, Giordano B, Diamantopoulos K, Pagano G, Chaudhuri KR, Politis M (2017). Non-motor symptom burden is associated with thalamic atrophy in Parkinson's disease. Author URL.
Wilson H, Yousaf T, Pagano G, Politis M (2017). Pain and Parkinson's disease. Author URL.
Wilson H, Yousaf T, Pagano G, Politis M (2017). Pain and Parkinson's disease. Author URL.
Wilson H, Pagano G, Niccolini F, Muhlert N, Coello C, Tziortzi A, Searle G, Gunn R, Rabiner E, Foltynie T, et al (2017). Phosphodiesterases and striatal pathways in Parkinson's disease. Author URL.
Pagano G, Wilson H, Niccolini F, Muhlert N, Coello C, Tziortzi A, Searle G, Gunn R, Rabiner E, Foltynie T, et al (2017). Phosphodiesterases and striatal pathways in Parkinson's disease. Author URL.
Wilson H, Pagano G, Niccolini F, Muhlert N, Coello C, Tziortzi A, Searle G, Gunn R, Rabiner E, Foltynie T, et al (2017). Phosphodiesterases and striatal pathways in Parkinson's disease. Author URL.
Pagano G, Yousaf T, Loane C, Polychronis S, Wilson H, Giordano B, Niccolini F, Politis M (2017). Predict Cognitive Decline with Clinical Markers in Parkinson's Disease. Author URL.
Pagano G, Yousaf T, Loane C, Polychronis S, Wilson H, Giordano B, Niccolini F, Politis M (2017). Predict cognitive decline with clinical markers in Parkinson's disease. Author URL.
Yousaf T, Pagano G, Niccolini F, Politis M (2017). Predict cognitive decline with non-clinical markers in Parkinson's disease. Author URL.
Yousaf T, Pagano G, Niccolini F, Politis M (2017). Predict cognitive decline with non-clinical markers in Parkinson's disease. Author URL.
Batash T, Newman H, Barak A, Zayit-Soudry S, Pras E, Banin E, Politis M, Loewenstein A, Neudorfer M (2017). Retinitis pigmentosa-associated cystoid macular edema has inflammatory optical density characteristics. Author URL.
Roussakis AA, Lao-Kaim N, Martin-Bastida A, Valle-Guzman N, Politis M, Foltynie T, Barker R, Piccini P (2017). Serotonin-to-dopamine transporter ratios in Parkinson's dyskinesias: the longitudinal study. Author URL.
Polychronis S, Niccolini F, Pagano G, Politis M (2017). Speech difficulties are linked to striatal dopaminergic deficits and cognitive decline in early de novo patients with Parkinson's disease. Author URL.
Polychronis S, Niccolini F, Pagano G, Politis M (2017). Speech difficulties are linked to striatal dopaminergic deficits and cognitive decline in early de novo patients with Parkinson's disease. Author URL.
Polychronis S, Dervenoulas G, Pagano G, Niccolini F, Politis M (2017). Swallowing difficulties and Parkinson's disease. Author URL.
Polychronis S, Dervenoulas G, Pagano G, Niccolini F, Politis M (2017). Swallowing difficulties and Parkinson's disease. Author URL.
Yousaf T, Pagano G, Niccolini F, Politis M (2017). TOMM40 polymorphism is associated with cognitive and CSF pathology in patients with dementia. Author URL.
Wilson H, Pagano G, Niccolini F, Muhlert N, Coello C, Mehta M, Searle G, Gunn R, Rabiner E, Foltynie T, et al (2017). The role of phosphodiesterase 4 in sleep disturbances in Parkinson's disease. Author URL.
Wilson H, Pagano G, Niccolini F, Muhlert N, Coello C, Mehta M, Searle G, Gunn R, Rabiner E, Foltynie T, et al (2017). The role of phosphodiesterase 4 in sleep disturbances in Parkinson's disease. Author URL.
Yousaf T, Pagano G, Niccolini F, Politis M (2016). Comorbidity and Parkinson's disease phenotype, dopaminergic function and CSF biomarkers. Author URL.
Li W, Lao-Kaim NP, Roussakis AA, Martin-Bastida A, Loane C, Valle-Guzman N, Kefalopoulou Z, Politis M, Foltynie T, Barker RA, et al (2016). Comparison of DAT and DOPA PET tracer for assessing severity and progression in patients with Parkinson's disease. Author URL.
Pagano G, Niccolini F, Politis M (2016). Constipation in early de novo Parkinson's disease: Prevalence and correlates with clinical features, imaging and non-imaging biomarkers. Author URL.
Yousaf T, Pagano G, Niccolini F, Politis M (2016). Excessive daytime sleepiness is mediated by loss of caudate dopaminergic function in Parkinson's disease. Author URL.
Bastida AM, Lao-Kaim N, Roussakis A-A, Politis M, Li W, Valle-Guzman N, Kefalopoulou Z, Paul G, Widner H, Foltynie T, et al (2016). Imaging nigrostriatal circuitry with 11C-PE2I PET and neuromelanin-sensitive MR in Parkinson's disease. Author URL.
Roussakis A-A, Lao-Kaim N, Bastida AM, Valle-Guzman N, Kefalopoulou Z, Paul G, Widner H, Politis M, Foltynie T, Barker RA, et al (2016). Increased serotonin-to-dopamine transporter ratios in Parkinson's disease dyskinesias: a longitudinal study. Author URL.
Roussakis A-A, Lao-Kaim N, Martin-Bastida A, Valle-Guzman N, Kefalopoulou Z, Paul-Visse G, Widner H, Politis M, Foltynie T, Barker R, et al (2016). LEVODOPA-INDUCED DYSKINESIA IN PARKINSON'S: a LONGITUDINAL PET STUDY. Author URL.
Wilson H, Niccolini F, Haider S, Marques TR, Pagano G, Coello C, Natesan S, Kapur S, Rabiner EA, Gunn RN, et al (2016). Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. Author URL.
Martin-Bastida A, Lao-Kaim NP, Roussakis AA, Li W, Politis M, Valle-Guzman N, Kefalopoulou Z, Paul G, Widner H, Foltynie T, et al (2016). Multimodal imaging assessment of nigrostriatal pathway in Parkinson's disease using 11C-PE2I PET and neuromelanin-sensitive MR. Author URL.
Wilson H, Niccolini F, Pellicano C, Piccini P, Politis M (2016). Staging and clinical correlates of cortical thinning in Parkinson's disease. Author URL.
Niccolini F, Pagano G, Fusar-Poli P, Wood A, Mrzljak L, Sampaio C, Politis M (2016). Striatal molecular alterations in Huntington's disease gene expansion carriers: a systematic review and meta-analysis of PET studies. Author URL.
Polychronis S, Pagano G, Politis M (2016). The role of diabetes mellitus and hyperglycemia in early de novo Parkinson's disease patients. Author URL.
Polychronis S, Pagano G, Politis M (2016). The role of striatal dopaminergic terminals in early de novo PD patients with speech impairment. Author URL.
Pagano G, Niccolini F, Politis M (2016). α-synuclein CSF levels correlate with urinary dysfunction in early de novo Parkinson's disease patients. Author URL.
Sauerbier A, Martinez-Martin P, Politis M, Rizos A, Troja N, Mulholland N, Vivian G, Cocoran B, Trivedi D, Perkins L, et al (2015). Dopamine transporter scan (DaTscan) and clinical global impression of severity of Parkinson's disease: Data from a non motor natural history study. Author URL.
Perkins L, Politis M, Niccolini F, Sauerbier A, Inniss R, Martin A, Trivedi D, Ray-Chaudhuri K (2015). Effect of acute non-oral dopaminergic (apomorphine and levodopa) treatment on non-motor symptoms in Parkinson's disease. Author URL.
Roussakis A-A, Politis M, Towey D, Piccini P (2015). Levodopa induced dyskinesias: increased serotonin to dopamine transporter ratios in the putamen of Parkinson's disease patients. Author URL.
Niccolini F, Foltynie T, Marques TR, Searle G, Natesan S, Kapur S, Rabiner E, Gunn R, Piccini P, Politis M, et al (2015). Loss of phosphodiesterase 10A signalling is associated with progression and severity in patients with Parkinson's disease. Author URL.
Bastida AM, Politis M, Loane C, Lao-Kaim N, Valle-Guzman N, Kefalopoulou Z, Paul G, Widner H, Foltynie T, Barker R, et al (2015). Nigral iron susceptibility in Parkinson's disease (PD). Author URL.
Roussakis A-A, Politis M, Towey D, Piccini P (2015). SEROTONIN-TO-DOPAMINE TRANSPORTER RATIOS IN THE STRIATUM OF PATIENTS WITH PARKINSON'S DISEASE: IMPACT ON LEVODOPA-INDUCED DYSKINESIAS. Author URL.
Martin-Bastida A, Politis M, Loane C, Lao-Kaim N, Valle-Guzman N, Kefalopoulou Z, Gesine P, Foltynie T, Barker R, Piccini P, et al (2015). SUSCEPTIBILITY WEIGHTED IMAGING TO DETECT NIGRAL IRON ACCUMULATION IN PARKINSON'S DISEASE. Author URL.
Marques TR, Natesan S, Niccolini F, Politis M, Gunn R, Searle G, Howes O, Rabiner E, Kapur S (2015). The role of Phosphodiesterase 10A in Schizophrenia: a Positron Emission Tomography study using [<SUP>11</SUP>C]IMA107. Author URL.
Niccolini F, Marques TR, Haider S, Muhlert N, Tzortzi AC, Loane C, Searle GE, Robertson N, Natesan S, Piccini P, et al (2014). Brain phosphodiesterase 10A (PDE-10A) density in early premanifest HD gene carriers. Author URL.
Niccolini F, Marques TR, Haider S, Muhlert N, Tzortzi AC, Loane C, Searle GE, Robertson N, Natesan S, Piccini P, et al (2014). Brain phosphodiesterase 10A (PDE-10A) density in early premanifest HD gene carriers. Author URL.
Niccolini F, Marques TR, Haider S, Searle G, Natesan S, Kapur S, Rabiner E, Gunn R, Tabrizi S, Politis M, et al (2014). Brain phosphodiesterase 10A (PDE-10A) density in early premanifest HD gene carriers. Author URL.
Wu K, Politis M, O'Sullivan SS, Lawrence AD, Warsi S, Bose S, Lees AJ, Piccini P (2014). Co-morbid impulse control disorders in Parkinson's disease: a positron emission tomography study. Author URL.
Wu K, Politis M, O'Sullivan SS, Lawrence AD, Warsi S, Lees A, Piccini P (2014). Problematic internet use in Parkinson's disease. Author URL.
Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhatia K, Jahanshahi M, Widner H, Rehncrona S, Brundin P, Bjoerklund A, et al (2014). Very long-term clinical outcome of fetal cell transplantation for Parkinson's disease. Author URL.
Politis M, Giannetti P, Niccolini F, Su P, Turkheimer F, Waldman A, Reynolds R, Nicholas R, Piccini P (2013). Decreased Microglial Activation Precedes Stabilization of Disability in Multiple Sclerosis Patients Treated with Natalizumab. Author URL.
Niccolini F, Giannetti P, Politis M, Su P, Turkheimer F, Waldman A, Reynolds R, Nicholas R, Piccini P (2013). In Vivo Detection of Thalamo-Cortical Pathology in Patients with Clinical Isolated Syndrome. Author URL.
Giannetti P, Politis M, Su P, Turkheimer F, Malik O, Keihaninejad S, Waldman A, Niccolini F, Reynolds R, Nicholas R, et al (2013). Microglia Activation in Clinically Isolated Syndrome: 11C11195PK-PET Change within Normal Appearing White Matter and Deep Grey Matter Structures. Author URL.
Politis M, Loane C, Pavese N, Brooks D, Chaudhuri K, Piccini P (2013). Sustained and Prolonged Striatal Dopamine Levels in Parkinson's Patients Following Enteral L-Dopa Gel Infusion: an in Vivo 11C-Raclopride PET Study. Author URL.
Loane C, Politis M, Wu K, O'Sullivan SS, Woodhead Z, Lawrence AD, Lees AJ, Piccini P (2012). Drug-cue elicited frontal and limbic dysfunction in Parkinson's disease patients with dopamine dysregulation syndrome. Author URL.
Wu K, O'Keeffe D, Politis M, O'Keeffe G, Bose S, Brooks DJ, Barker R, Piccini P (2012). IN VIVO EVIDENCE OF COMT VAL158MET FUNCTIONAL POLYMORPHISM MODULATES DIFFERENT LEVELS OF DOPAMINE TURNOVER IN PARKINSON'S DISEASE: AN 18F-DOPA PET STUDY. Author URL.
Garvey L, Pavese N, Politis M, Ramlackhansingh A, Taylor-Robinson S, Brooks D, Winston A (2012). Microglial cell activation is visualised with [11C]-PK11195 Positron Emission Tomography (PET) in neuro-asymptomatic HIV infected subjects on effective antiretroviral therapy. Author URL.
Politis M, Loane C, Wu K, O'Sullivan S, Woodhead Z, Kiferle L, Lawrence AD, Lees AJ, Piccini P (2012). Neural correlates of hypersexuality in Parkinson's disease. Author URL.
Giannetti P, Politis M, Su P, Turkheimer FE, Malik O, Keihaninejad S, Wu K, Reynolds R, Nicholas R, Piccini P, et al (2012). PK11195-PET Enhancement in Black Holes Correlates with Disability and Outcome in Progressive Multiple Sclerosis. Author URL.
Politis M, Wu K, Loane C, Kiferle L, Molloy S, Bain P, Brooks D, Piccini P (2012). Serotonergic mediated peak-dose L-DOPA-induced dyskinesias in Parkinson's disease. Author URL.
Loane C, Politis M, Wu K, Brooks DJ, Piccini P (2012). Serotonergic presynaptic terminal density in caudate nucleus inversely correlates with severity of action-postural tremor in PD. Author URL.
Giannetti P, Politis M, Su P, Turkheimer F, Wu K, Reynolds R, Nicholas R, Piccini P (2011). Two different roles for microglia in vivo in T1 black holes in relapsing and progressive multiple sclerosis?. Author URL.
Politis M, Giannetti P, Su P, Turkheimer F, Keihaninejad S, Wu K, Waldman A, Reynolds R, Nicholas R, Piccini P, et al (2010). Cortical Microglial Activation is Associated with Disability in Secondary Progressive Multiple Sclerosis: an <i>In Vivo</i> Imaging Study. Author URL.
Wu K, Politis M, O'Sullivan S, Bose S, Lees A, Piccini P (2010). Impulse Control Disorders Subtypes in Parkinson's Disease: Clinical and PET Correlations. Author URL.
Wu K, Politis M, Warsi S, Loane C, O'Sullivan S, Lees A, Piccini P (2010). Measuring Severity of Impulse Control Disorders in Parkinson's Disease Using Objective Validated Questionnaire. Author URL.
Wu K, O'Sullian S, Politis M, Bose S, Lees A, Piccini P (2010). REWARDING VISUAL CUES INCREASE DOPAMINE NEUROTRANSMISSION IN PARKINSON'S PATIENTS WITH IMPULSE CONTROL DISORDERS: a PET STUDY. Author URL.
Politis M, Wu K, Loane C, Kiferle L, Molloy S, Bain P, Brooks DJ, Piccini P (2010). Serotonergic Involvement in L-DOPA-Induced Dyskinesia. Author URL.
Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, Piccini P (2010). Serotonergic Terminals Are Differentially Affected in Parkinson's Disease: an <i>In Vivo</i> <SUP>11</SUP>C-DASB PET Study. Author URL.
O'Sullivan SS, Politis M, Wu K, Lawrence AD, Evans AH, Bose SK, Lees AJ, Piccini P (2009). Increased dopamine neurotransmission in Parkinson's patients with Impulse control disorders in response to rewarding visual stimuli: a pilot study. Author URL.
Politis M, Pavese N, Tai YF, Kiferle L, Brooks DJ, Tabrizi SJ, Barker RA, Piccini P (2009). The limbic-circuitry of Huntington's disease: a combined neuroimaging approach. Author URL.
Politis M, Piccini P, Pavese N, Koh S-B, Brooks DJ (2007). Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease:: an in vivo <SUP>11</SUP>C-raclopride PET study. Author URL.
